(Q33852002)

29 July 2017

1 reference

title

Antiretroviral therapy of HIV infection in children (English)

1 reference

29 July 2017

main subject

anti-retroviral agent

0 references

author name string

Palumbo PE

series ordinal

1

1 reference

29 July 2017

publication date

1 February 2000

1 reference

Pediatric Clinics of North America

29 July 2017

published in

1 reference

29 July 2017

volume

47

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

155-169

1 reference

Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Zidovudine, Didanosine, or Both as the Initial Treatment for Symptomatic HIV-Infected Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Surrogate end points in clinical trials: are we being misled?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobuli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

A phase I/II study of the protease inhibitor indinavir in children with HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Decay characteristics of HIV-1-infected compartments during combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Comparative trial of two dosages of zalcitabine in zidovudine-experienced children with advanced human immunodeficiency virus disease. Pediatric AIDS Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Viral dynamics in human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970199-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0031-3955(05)70199-1

1 reference

29 July 2017

1 reference